PepGen Inc. shareholders approved Ratification of appointment of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-18 meeting.
“Proposal 2 - Ratification of Appointment of Independent Registered Accounting Firm The Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. Votes For Votes Against Abstentions 54,556,255 77,083 17,507 There were zero broker non-votes regarding this proposal.”
Shareholder Votes
PepGen Inc. shareholders approved Election of three Class I directors to serve until the 2029 annual meeting at the 2026-06-18 meeting.
“Proposal 1 - Election of Directors The Company’s stockholders elected the three Class I directors to the Company’s board of directors, to serve until the 2029 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal. Director Nominee Votes For Votes Withheld Howard Mayer, M.D. 36,111,969 8,502,248 Joshua Resnick, M.D., M.B.A. 35,766,232 8,847,985 Lisa Wyman, M.S. 39,423,497 5,190,720 There were 10,036,628 broker non-votes regarding the election of each of Howard Mayer, Joshua Resnick, and Lisa Wyman.”
Earnings Releases
PepGen Inc. reported financial results for the quarter and year-ended December 31, 2025.
“PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the quarter and year-ended December 31, 2025, and recent corporate highlights.”
Lisa Wyman was appointed as Director at PepGen Inc..
“On March 27, 2025, the Board of Directors (the “Board”) of PepGen Inc. (“PepGen” or the “Company”), on the recommendation of the Nominating and Corporate Governance Committee of the Board, unanimously appointed Mitchell Finer, Ph.D. and Lisa Wyman to fill newly created vacancies on the Board resulting from the expansion of the number of members of the Board from six to eight.”
Mitchell Finer was appointed as Director at PepGen Inc..
“On March 27, 2025, the Board of Directors (the “Board”) of PepGen Inc. (“PepGen” or the “Company”), on the recommendation of the Nominating and Corporate Governance Committee of the Board, unanimously appointed Mitchell Finer, Ph.D. and Lisa Wyman to fill newly created vacancies on the Board resulting from the expansion of the number of members of the Board from six to eight.”
Michelle L. Mellion resigned as Chief Medical Officer at PepGen Inc..
“On March 24, 2025, Michelle L. Mellion, MD resigned from her position as Chief Medical Officer of PepGen Inc.”
Christopher Ashton resigned as Director at PepGen Inc..
“On September 16, 2024, Christopher Ashton, Ph.D., provided notice of his resignation from the board of directors (the “Board”) of PepGen Inc. (the “Company”), effective as of September 30, 2024.”
Earnings Releases
PepGen Inc. reported financial results for the quarter ended March 31, 2024.
“On May 14, 2024, PepGen Inc. announced its financial results for the quarter ended March 31, 2024 and other business updates.”
Governance Changes
PepGen Inc.: Adopted second amended and restated bylaws to revise advance notice provisions, address universal proxy rules, update technical changes, and clarify meeting procedures and exclusive jurisdiction (effective 2024-03-15).
“On March 15, 2024, the board of directors (the “Board”) of PepGen Inc. (the “Company”) approved and adopted the second amended and restated by-laws (the “Second Amended and Restated By-laws”) of the Company, effective immediately. The Second Amended and Restated By-laws amend certain of the provisions of Article I, Sections 2, 6, 8, and 9, and Article VI, Sections 8 and 9. Among other things, the amendments set forth in the Second Amended and Restated By-laws: (1) revise the procedures and disclosure requirements set forth in the advance notice by-law provisions; (2) address the universal proxy rules adopted by the U.S. Securities and Exchange Commission, by clarifying that no person may solicit proxies in support of a director nominee other than the Board’s nominees unless such person has complied with Rule 14a-19 under the Securities Exchange Act of 1934, as amended (“Rule 14a-19”), including applicable notice and solicitation requirements; (3) require that a stockholder directly or”
Earnings Releases
PepGen Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.
“On March 6, 2024, PepGen Inc. announced its financial results for the year ended December 31, 2023 and other business updates.”
Material Agreements
PepGen Inc. entered into Underwriting Agreement with Leerink Partners LLC valued at Underwriting Agreement for 7,530,000 shares of common stock at $10.635 per share, net proceeds appro (effective 2024-02-06).
“On February 6, 2024, PepGen Inc. (the " Company ") entered into an underwriting agreement (the " Underwriting Agreement ") with Leerink Partners LLC, as underwriter, pursuant to which the Company agreed to issue and sell an aggregate of 7,530,000 shares (the " Shares ") of its common stock, par value $0.0001 per share (the " Common Stock "), at a price to the public of $10.635 per share.”
Howard Mayer was appointed as Director at PepGen Inc..
“On November 10, 2023, the Board of Directors (the “Board”) of PepGen Inc. (“PepGen”) on the recommendation of the Nominating and Corporate Governance Committee of the Board, unanimously appointed Howard Mayer to fill a newly created vacancy on the Board resulting from the expansion of the number of members of the Board from six to seven.”
Earnings Releases
PepGen Inc. reported the third quarter ended September 30, 2023 results: net income Net loss was $23.3 million.
“PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the third quarter ended September 30, 2023 and highlighted recent corporate developments.”
Earnings Releases
PepGen Inc. reported the second quarter ended June 30, 2023 results: net income Net loss was $19.5 million for the three months ended June 30, 2023.
“PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the second quarter ended June 30, 2023 and highlighted recent corporate developments.”
Material Agreements
PepGen Inc. entered into At-The-Market Equity Offering Sales Agreement with Stifel, Nicolaus & Company, Incorporated valued at up to $100.0 million (effective 2023-08-08).
“On August 8, 2023, PepGen Inc. (the “Company”) entered into an At-The-Market Equity Offering Sales Agreement (the “Agreement”) with Stifel, Nicolaus & Company, Incorporated (“Stifel”), under which the Company may offer and sell, from time to time at its sole discretion, shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $100.0 million after the date of the Agreement through Stifel as its sales agent.”
Shareholder Votes
PepGen Inc. shareholders approved Ratification of Appointment of Independent Registered Accounting Firm at the 2023-06-22 meeting.
“The Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.”
Shareholder Votes
PepGen Inc. shareholders approved Election of Directors at the 2023-06-22 meeting.
“The Company’s stockholders elected the two Class I directors to the Company’s board of directors, to serve until the 2026 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal.”
Earnings Releases
PepGen Inc. reported the quarter ended March 31, 2023 results: net income $16.3 million.
“Net loss was $16.3 million for the three months ended March 31, 2023, compared to $18.2 million for the same period in 2022.”
Earnings Releases
PepGen Inc. reported financial results for the fourth quarter and full year ended December 31, 2022.
“PepGen Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Developments”
Earnings Releases
PepGen Inc. reported the third quarter ended September 30, 2022 results: net income Net loss was $18.6 million for the three months ended September 30, 2022.
“PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the third quarter ended September 30, 2022”
Habib J. Dable was appointed as Director at PepGen Inc..
“Effective September 20, 2022, the Board of Directors (the “Board”) of PepGen Inc. (“PepGen”) on the recommendation of the Nominating and Corporate Governance Committee of the Board, unanimously appointed Habib J. Dable to fill a newly created vacancy on the Board”
Caroline Godfrey changed role as Senior Vice President of Discovery at PepGen Inc..
“On July 19, 2022, PepGen Inc. (“PepGen”) was notified that Caroline Godfrey would be transitioning from her role as Senior Vice President of Discovery to member of PepGen’s Scientific Advisory Board, effective August 1, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.